Johnson & Johnson (NYSE:JNJ) is Ellsworth Advisors LLC’s 9th Largest Position

Ellsworth Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 249.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,109 shares of the company’s stock after purchasing an additional 29,329 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Ellsworth Advisors LLC’s holdings, making the stock its 9th biggest position. Ellsworth Advisors LLC’s holdings in Johnson & Johnson were worth $6,662,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alaska Permanent Fund Corp boosted its holdings in Johnson & Johnson by 1.4% during the first quarter. Alaska Permanent Fund Corp now owns 159,720 shares of the company’s stock worth $25,266,000 after buying an additional 2,267 shares in the last quarter. Adams Asset Advisors LLC lifted its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. Adams Asset Advisors LLC now owns 5,762 shares of the company’s stock valued at $911,000 after acquiring an additional 70 shares during the period. Stolper Co grew its holdings in shares of Johnson & Johnson by 9.8% in the 1st quarter. Stolper Co now owns 32,451 shares of the company’s stock worth $5,133,000 after acquiring an additional 2,899 shares during the period. Welch Group LLC increased its stake in Johnson & Johnson by 4.7% in the 1st quarter. Welch Group LLC now owns 326,765 shares of the company’s stock valued at $51,691,000 after purchasing an additional 14,527 shares in the last quarter. Finally, Richard P Slaughter Associates Inc grew its holdings in Johnson & Johnson by 0.9% in the first quarter. Richard P Slaughter Associates Inc now owns 9,246 shares of the company’s stock valued at $1,463,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $164.49 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company’s 50 day simple moving average is $162.89 and its 200 day simple moving average is $154.66. The stock has a market capitalization of $395.87 billion, a PE ratio of 10.25, a P/E/G ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the firm posted $2.66 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Ratings Changes

Several research firms have recently issued reports on JNJ. Citigroup lifted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.